Literature DB >> 16845628

Differential antigenic hierarchy associated with spontaneous recovery from hepatitis C virus infection: implications for vaccine design.

Susan Smyk-Pearson1, Ian A Tester, Dennis Lezotte, Anna W Sasaki, David M Lewinsohn, Hugo R Rosen.   

Abstract

BACKGROUND: Cellular immune responses play a central role in the control of hepatitis C virus (HCV) infection, and in some individuals the adaptive immune response can spontaneously eradicate HCV infection. The development of vaccine candidates to prevent the spread of this infection remains a top priority; however, understanding the correlates of effective immunological containment is an important prerequisite.
METHODS: Using 750 overlapping peptides, we directly characterized ex vivo total and subgenomic HCV-specific CD4(+) and CD8(+) T cell responses in a large cohort of participants with either chronic infection or spontaneously resolved infection.
RESULTS: In chronic infection, the frequency of total CD4(+) T cells specific for HCV averaged 0.06%, compared with 0.38% in resolved infection. Total HCV-specific CD4(+) and CD8(+) T cell responses were strongly correlated in the setting of spontaneous resolution but not in the setting of viral persistence. NS3 protein-specific responses comprised a significantly greater proportion of the total response in resolved infection than in chronic infection, whereas responses to different regions comprised a larger proportion of responses in chronic infection.
CONCLUSION: Because these data comprehensively define the breadth, specificity, and threshold of the T cell response associated with spontaneous recovery from HCV infection, they have important implications in the development of multigenic vaccine candidates for this common infection.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16845628     DOI: 10.1086/505714

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  29 in total

Review 1.  Hepatitis C virus-specific cytotoxic T cell response restoration after treatment-induced hepatitis C virus control.

Authors:  Juan-Ramón Larrubia; Elia Moreno-Cubero; Joaquín Miquel; Eduardo Sanz-de-Villalobos
Journal:  World J Gastroenterol       Date:  2015-03-28       Impact factor: 5.742

2.  HCV-specific immune responses induced by CIGB-230 in combination with IFN-α plus ribavirin.

Authors:  Yalena Amador-Cañizares; Gillian Martínez-Donato; Liz Alvarez-Lajonchere; Claudia Vasallo; Mariacarla Dausá; Daylen Aguilar-Noriega; Carmen Valenzuela; Ivette Raíces; Jean Dubuisson; Czeslaw Wychowski; Zurina Cinza-Estévez; Marlén Castellanos; Magdalys Núñez; Anny Armas; Yaimé González; Ismariley Revé; Ivis Guerra; Angel Pérez Aguiar; Santiago Dueñas-Carrera
Journal:  World J Gastroenterol       Date:  2014-01-07       Impact factor: 5.742

3.  Increased degranulation of natural killer cells during acute HCV correlates with the magnitude of virus-specific T cell responses.

Authors:  Sandy Pelletier; Christian Drouin; Nathalie Bédard; Salim I Khakoo; Julie Bruneau; Naglaa H Shoukry
Journal:  J Hepatol       Date:  2010-07-17       Impact factor: 25.083

4.  Immunologic evidence for lack of heterologous protection following resolution of HCV in patients with non-genotype 1 infection.

Authors:  Julian Schulze Zur Wiesch; Georg M Lauer; Joerg Timm; Thomas Kuntzen; Martin Neukamm; Andrew Berical; Andrea M Jones; Brian E Nolan; Steve A Longworth; Victoria Kasprowicz; Cory McMahon; Alysse Wurcel; Ansgar W Lohse; Lia L Lewis-Ximenez; Raymond T Chung; Arthur Y Kim; Todd M Allen; Bruce D Walker
Journal:  Blood       Date:  2007-05-02       Impact factor: 22.113

5.  Hepatitis C genotype 1 mosaic vaccines are immunogenic in mice and induce stronger T-cell responses than natural strains.

Authors:  Karina Yusim; Rebecca Dilan; Erica Borducchi; Kelly Stanley; Elena Giorgi; William Fischer; James Theiler; Joseph Marcotrigiano; Bette Korber; Dan H Barouch
Journal:  Clin Vaccine Immunol       Date:  2012-12-05

6.  A self-adjuvanting lipopeptide-based vaccine candidate for the treatment of hepatitis C virus infection.

Authors:  Brendon Y Chua; Emily M Eriksson; Lorena E Brown; Weiguang Zeng; Eric J Gowans; Joseph Torresi; David C Jackson
Journal:  Vaccine       Date:  2008-04-07       Impact factor: 3.641

7.  Cell-mediated immune responses directed against hepatitis C virus (HCV) alternate reading frame protein (ARFP) are undetectable during acute infection.

Authors:  Christian Drouin; Stéphanie Lamarche; Julie Bruneau; Hugo Soudeyns; Naglaa H Shoukry
Journal:  J Clin Virol       Date:  2009-12-01       Impact factor: 3.168

8.  High, broad, polyfunctional, and durable T cell immune responses induced in mice by a novel hepatitis C virus (HCV) vaccine candidate (MVA-HCV) based on modified vaccinia virus Ankara expressing the nearly full-length HCV genome.

Authors:  Carmen E Gómez; Beatriz Perdiguero; María Victoria Cepeda; Lidia Mingorance; Juan García-Arriaza; Andrea Vandermeeren; Carlos Óscar S Sorzano; Mariano Esteban
Journal:  J Virol       Date:  2013-04-17       Impact factor: 5.103

9.  Signatures of protective memory immune responses during hepatitis C virus reinfection.

Authors:  Mohamed S Abdel-Hakeem; Nathalie Bédard; Donald Murphy; Julie Bruneau; Naglaa H Shoukry
Journal:  Gastroenterology       Date:  2014-07-16       Impact factor: 22.682

10.  Upregulation of PD-1 expression on circulating and intrahepatic hepatitis C virus-specific CD8+ T cells associated with reversible immune dysfunction.

Authors:  Lucy Golden-Mason; Brent Palmer; Jared Klarquist; John A Mengshol; Nicole Castelblanco; Hugo R Rosen
Journal:  J Virol       Date:  2007-06-13       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.